A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)

Trial Profile

A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Baltaleucel-T (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CITADEL
  • Sponsors Cell Medica
  • Most Recent Events

    • 07 Apr 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
    • 07 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
    • 27 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top